Clinical Trial

Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort

Recruiting Phase 3

Summary

The insertion of a urinary catheter in a patient undergoing a surgical procedure, especially urinary interventions, may lead to catheter-related bladder discomfort (CRBD) with varying degrees of severity during the postoperative period. Paracetamol is a drug with proven efficacy for the management of mild and moderate postoperative pain. Tramadol is a centrally acting, synthetic opioid analgesic with weak opioid agonist properties. It inhibits the detrusor activity by inhibition of type-1 muscarinic (M1) and type-3 muscarinic (M3) receptors. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, with analgesic, sedative, anxiolysis, sympatholytic, and sedative properties, is a very useful associated agent for general anesthesia.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2024-02-21; most recent amendment 2026-01-04.

Status change: Not Yet Recruiting → Recruiting 2024-03-13

Trial Details

NCT Number	NCT06274333
Lead Sponsor	Al-Azhar University Collaborators: Benha University
Conditions	Percutaneous Nephrolithotripsy (PCNL)
Enrollment	60 participants
Start Date	2024-02-28
Primary Completion	2026-08-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-06